> top > docs > PMC:7346000 > spans > 29445-31786 > annotations

PMC:7346000 / 29445-31786 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
786 662-675 CellLine denotes NORTE-01-0145 CVCL:K414
787 693-706 CellLine denotes NORTE-01-0145 CVCL:K414
789 1138-1144 Disease denotes Stress MESH:D000079225

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T239 1381-1384 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T240 1891-1894 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T241 2106-2109 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T242 2325-2328 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T229 399-400 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T230 411-412 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T231 991-994 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T232 1711-1714 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T233 1790-1792 http://www.ebi.ac.uk/efo/EFO_0000265 denotes Da
T234 1921-1922 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T235 2015-2017 http://www.ebi.ac.uk/efo/EFO_0000265 denotes Da

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T208 1419-1421 Chemical denotes NV http://purl.obolibrary.org/obo/CHEBI_73825

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T38 1158-1163 http://purl.obolibrary.org/obo/GO_0007568 denotes Aging

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T162 0-20 Sentence denotes Author Contributions
T163 21-274 Sentence denotes Conceptualization, M.H., A.A., and A.C.; writing—original draft preparation, A.A., A.C., M.H., F.L.v.d.V., J.D.J., C.L.-F., P.K., O.A.C., D.S.P., R.K.; writing—review and editing, M.H., A.A., A.C., F.L.v.d.V., J.D.J., C.L.-F., P.K., O.A.C., D.S.P., R.K.
T164 275-351 Sentence denotes All authors have read and agreed to the published version of the manuscript.
T165 353-360 Sentence denotes Funding
T166 361-721 Sentence denotes AC was supported by the Fundação para a Ciência e a Tecnologia (FCT) (CEECIND/03628/2017, UIDB/50026/2020 and UIDP/50026/2020), and the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, through the European Regional Development Fund (ERDF) (NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023).
T167 722-771 Sentence denotes This research received no other external funding.
T168 773-794 Sentence denotes Conflicts of Interest
T169 795-847 Sentence denotes M.H. received research funding by Gilead and Pfizer.
T170 848-985 Sentence denotes D.S.P. receives research support and/or serves on advisory boards for Amplyx, Cidara, Scynexis, N8 Medical, Merck, Regeneron, and Pfizer.
T171 986-1487 Sentence denotes P.K. has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, and is an adivisor to, or received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, NOXXON Pharma NV., and University Hospital, LMU Munich outside the submitted work.
T172 1488-2341 Sentence denotes O.A.C. is supported by the German Federal Ministry of Research and Education; is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany’s Excellence Strategy (CECAD, EXC 2030 - 390661388); has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, MSD, Pfizer, and Scynexis; is a consultant to Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche, Roche Diagnostics, MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, MSD, and Pfizer.